Immunitybio Net Debt from 2010 to 2024

IBRX Stock

USD 5.04 0.06 1.18%

Immunitybio Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2024. Net Debt is the total debt of Immunitybio minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2014-12-31

Previous Quarter

868.9 M

Current Value

519.8 M

Quarterly Volatility

321.9 M

Yuan Drop

Covid

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.

Check out the analysis of Immunitybio Correlation against competitors.

For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Net Debt Growth Pattern

Below is the plot of the Net Debt of Immunitybio over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Immunitybio's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Immunitybio Net Debt Regression Statistics

	Arithmetic Mean	134,416,233
	Coefficient Of Variation	185.17
	Mean Deviation	213,046,578
	Median	1,410,000
	Standard Deviation	248,898,410
	Sample Variance	61950.4T
	Range	792.6M
	R-Value	0.79
	Mean Square Error	25052.7T
	R-Squared	0.62
	Significance	0.0005
	Slope	43,981,362
	Total Sum of Squares	867305.9T

Immunitybio Net Debt History

	2024	484.3 M
	2023	461.3 M
	2022	619.1 M
	2021	464.6 M
	2020	240.6 M
	2019	-660 K
	2018	-9.9 M

Other Fundumenentals of Immunitybio

Net Debt To E B I T D A

Immunitybio Net Debt component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Long Term Debt	Net Invested Capital	Long Term Investments	Capital Stock	Net Working Capital	Deferred Long Term Liab	Short Long Term Debt
Total Assets		-0.38	-0.82	0.61	-0.75	0.64	0.23	0.68	0.95	0.45	0.57	0.7	-0.31	0.73	0.65	-0.64	0.53	0.41	-0.7	0.55	-0.03	-0.33	0.56
Total Stockholder Equity	-0.38		0.28	-0.91	0.86	-0.64	0.03	-0.92	-0.24	-0.44	-0.64	-0.87	0.7	-0.83	-0.85	0.91	-0.67	-0.28	0.87	-0.75	-0.06	0.68	-0.82
Current Deferred Revenue	-0.82	0.28		-0.53	0.72	-0.6	-0.45	-0.57	-0.69	-0.32	-0.57	-0.65	0.52	-0.58	-0.56	0.58	-0.32	-0.27	0.51	-0.36	0.02	0.32	-0.41
Net Debt	0.61	-0.91	-0.53		-0.93	0.86	0.04	0.93	0.44	0.68	0.66	0.89	-0.62	0.91	0.86	-0.95	0.51	0.53	-0.94	0.61	-0.19	-0.53	0.76
Retained Earnings	-0.75	0.86	0.72	-0.93		-0.78	-0.17	-0.97	-0.6	-0.47	-0.75	-0.98	0.73	-0.91	-0.91	0.96	-0.68	-0.35	0.91	-0.75	-0.05	0.67	-0.82
Accounts Payable	0.64	-0.64	-0.6	0.86	-0.78		0.05	0.71	0.45	0.81	0.56	0.69	-0.5	0.85	0.68	-0.83	0.21	0.52	-0.73	0.32	-0.54	-0.15	0.59
Net Receivables	0.23	0.03	-0.45	0.04	-0.17	0.05		0.09	0.16	-0.05	0.01	0.12	-0.26	0.07	0.1	-0.05	0.11	-0.08	-0.04	0.12	0.09	-0.1	0.1
Total Liab	0.68	-0.92	-0.57	0.93	-0.97	0.71	0.09		0.56	0.46	0.75	0.98	-0.68	0.88	0.94	-0.95	0.72	0.36	-0.95	0.79	0.1	-0.75	0.85
Total Current Assets	0.95	-0.24	-0.69	0.44	-0.6	0.45	0.16	0.56		0.33	0.4	0.58	-0.09	0.58	0.5	-0.46	0.49	0.43	-0.59	0.47	0.09	-0.29	0.4
Short Term Debt	0.45	-0.44	-0.32	0.68	-0.47	0.81	-0.05	0.46	0.33		0.36	0.35	-0.21	0.6	0.43	-0.57	-0.09	0.8	-0.65	0.01	-0.79	0.13	0.32
Intangible Assets	0.57	-0.64	-0.57	0.66	-0.75	0.56	0.01	0.75	0.4	0.36		0.72	-0.76	0.62	0.81	-0.82	0.54	0.02	-0.71	0.66	-0.05	-0.62	0.84
Common Stock	0.7	-0.87	-0.65	0.89	-0.98	0.69	0.12	0.98	0.58	0.35	0.72		-0.7	0.87	0.9	-0.93	0.73	0.28	-0.88	0.79	0.2	-0.77	0.81
Short Term Investments	-0.31	0.7	0.52	-0.62	0.73	-0.5	-0.26	-0.68	-0.09	-0.21	-0.76	-0.7		-0.61	-0.72	0.76	-0.51	0.09	0.56	-0.61	-0.04	0.58	-0.74
Capital Surpluse	0.73	-0.83	-0.58	0.91	-0.91	0.85	0.07	0.88	0.58	0.6	0.62	0.87	-0.61		0.79	-0.92	0.65	0.41	-0.86	0.7	-0.14	-0.38	0.79
Property Plant Equipment	0.65	-0.85	-0.56	0.86	-0.91	0.68	0.1	0.94	0.5	0.43	0.81	0.9	-0.72	0.79		-0.91	0.7	0.25	-0.91	0.79	0.07	-0.75	0.89
Net Tangible Assets	-0.64	0.91	0.58	-0.95	0.96	-0.83	-0.05	-0.95	-0.46	-0.57	-0.82	-0.93	0.76	-0.92	-0.91		-0.6	-0.32	0.91	-0.71	0.11	0.62	-0.87
Long Term Debt	0.53	-0.67	-0.32	0.51	-0.68	0.21	0.11	0.72	0.49	-0.09	0.54	0.73	-0.51	0.65	0.7	-0.6		-0.14	-0.62	0.98	0.56	-0.68	0.8
Net Invested Capital	0.41	-0.28	-0.27	0.53	-0.35	0.52	-0.08	0.36	0.43	0.8	0.02	0.28	0.09	0.41	0.25	-0.32	-0.14		-0.56	-0.13	-0.46	0.09	-0.03
Long Term Investments	-0.7	0.87	0.51	-0.94	0.91	-0.73	-0.04	-0.95	-0.59	-0.65	-0.71	-0.88	0.56	-0.86	-0.91	0.91	-0.62	-0.56		-0.7	0.08	0.61	-0.79
Capital Stock	0.55	-0.75	-0.36	0.61	-0.75	0.32	0.12	0.79	0.47	0.01	0.66	0.79	-0.61	0.7	0.79	-0.71	0.98	-0.13	-0.7		0.46	-0.74	0.9
Net Working Capital	-0.03	-0.06	0.02	-0.19	-0.05	-0.54	0.09	0.1	0.09	-0.79	-0.05	0.2	-0.04	-0.14	0.07	0.11	0.56	-0.46	0.08	0.46		-0.59	0.07
Deferred Long Term Liab	-0.33	0.68	0.32	-0.53	0.67	-0.15	-0.1	-0.75	-0.29	0.13	-0.62	-0.77	0.58	-0.38	-0.75	0.62	-0.68	0.09	0.61	-0.74	-0.59		-0.65
Short Long Term Debt	0.56	-0.82	-0.41	0.76	-0.82	0.59	0.1	0.85	0.4	0.32	0.84	0.81	-0.74	0.79	0.89	-0.87	0.8	-0.03	-0.79	0.9	0.07	-0.65

Click cells to compare fundamentals

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	461.3 M	484.3 M
Net Debt To EBITDA	(1.06)	(1.00)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunitybio Net Debt from 2010 to 2024

Latest Immunitybio's Net Debt Growth Pattern

Immunitybio Net Debt Regression Statistics

Immunitybio Net Debt History

Other Fundumenentals of Immunitybio

Immunitybio Net Debt component correlations

About Immunitybio Financial Statements

Also Currently Popular

Additional Tools for Immunitybio Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY